-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Contrasting Aerovate Therapeutics (NASDAQ:AVTE) and Concert Pharmaceuticals (NASDAQ:CNCE)
Contrasting Aerovate Therapeutics (NASDAQ:AVTE) and Concert Pharmaceuticals (NASDAQ:CNCE)
Aerovate Therapeutics (NASDAQ:AVTE – Get Rating) and Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.
Analyst Ratings
This is a summary of recent ratings and target prices for Aerovate Therapeutics and Concert Pharmaceuticals, as reported by MarketBeat.
Get Aerovate Therapeutics alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Aerovate Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Concert Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
Aerovate Therapeutics currently has a consensus price target of $40.50, indicating a potential upside of 61.68%. Concert Pharmaceuticals has a consensus price target of $19.67, indicating a potential upside of 178.96%. Given Concert Pharmaceuticals' higher possible upside, analysts plainly believe Concert Pharmaceuticals is more favorable than Aerovate Therapeutics.
Profitability
This table compares Aerovate Therapeutics and Concert Pharmaceuticals' net margins, return on equity and return on assets.Net Margins | Return on Equity | Return on Assets | |
Aerovate Therapeutics | N/A | -28.64% | -27.70% |
Concert Pharmaceuticals | N/A | -109.43% | -76.65% |
Valuation and Earnings
This table compares Aerovate Therapeutics and Concert Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Aerovate Therapeutics | N/A | N/A | -$22.96 million | ($1.57) | -15.96 |
Concert Pharmaceuticals | $32.58 million | 10.37 | -$80.05 million | ($3.21) | -2.20 |
Aerovate Therapeutics has higher earnings, but lower revenue than Concert Pharmaceuticals. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Aerovate Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Concert Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.
Insider & Institutional Ownership
70.6% of Concert Pharmaceuticals shares are owned by institutional investors. 17.8% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 11.3% of Concert Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Aerovate Therapeutics beats Concert Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
About Aerovate Therapeutics
(Get Rating)
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
About Concert Pharmaceuticals
(Get Rating)
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Aerovate Therapeutics (NASDAQ:AVTE – Get Rating) and Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.
好氧治療(納斯達克:AVTE-GET評級)和協和製藥(納斯達克:CNCE-GET評級)都是小盤醫療公司,但哪一家更好?我們將根據這兩家公司的股息、估值、分析師建議、機構所有權、盈利能力、風險和收益的實力進行比較。
Analyst Ratings
分析師評級
This is a summary of recent ratings and target prices for Aerovate Therapeutics and Concert Pharmaceuticals, as reported by MarketBeat.
據MarketBeat報道,這是Aerovate治療公司和Concert製藥公司最近的評級和目標價格摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Aerovate Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Concert Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
充氣治療學 | 0 | 0 | 2 | 0 | 3.00 |
演唱會製藥 | 0 | 0 | 3 | 0 | 3.00 |
Aerovate Therapeutics currently has a consensus price target of $40.50, indicating a potential upside of 61.68%. Concert Pharmaceuticals has a consensus price target of $19.67, indicating a potential upside of 178.96%. Given Concert Pharmaceuticals' higher possible upside, analysts plainly believe Concert Pharmaceuticals is more favorable than Aerovate Therapeutics.
Aerovate治療公司目前的共識目標價為40.50美元,表明潛在漲幅為61.68%。Concert PharmPharmticals的共識目標價為19.67美元,表明潛在漲幅為178.96。考慮到Concert製藥公司更高的可能上行空間,分析師們顯然認為Concert製藥公司比Aerovate治療公司更有利。
Profitability
盈利能力
Net Margins | Return on Equity | Return on Assets | |
Aerovate Therapeutics | N/A | -28.64% | -27.70% |
Concert Pharmaceuticals | N/A | -109.43% | -76.65% |
淨利潤率 | 股本回報率 | 資產回報率 | |
充氣治療學 | 不適用 | -28.64% | -27.70% |
演唱會製藥 | 不適用 | -109.43% | -76.65% |
Valuation and Earnings
估值和收益
This table compares Aerovate Therapeutics and Concert Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
此表比較了Aerovate治療公司和Concert製藥公司的營收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Aerovate Therapeutics | N/A | N/A | -$22.96 million | ($1.57) | -15.96 |
Concert Pharmaceuticals | $32.58 million | 10.37 | -$80.05 million | ($3.21) | -2.20 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
充氣治療學 | 不適用 | 不適用 | -2,296萬元 | ($1.57) | -15.96 |
演唱會製藥 | 3,258萬美元 | 10.37 | -805萬美元 | ($3.21) | -2.20 |
Aerovate Therapeutics has higher earnings, but lower revenue than Concert Pharmaceuticals. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Aerovate治療公司比Concert製藥公司有更高的收益,但收入更低。Aerovate治療公司的市盈率低於Concert製藥公司,這表明它目前是兩隻股票中更負擔得起的一隻。
Volatility and Risk
波動性和風險
Aerovate Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Concert Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.
Aerovate Treateutics的貝塔係數為0.8,這表明其股價的波動性比標準普爾500指數低20%。相比之下,Concert PharmPharmticals的貝塔係數為0.3,這表明其股價的波動性比標準普爾500指數低70%。
Insider & Institutional Ownership
內部人與機構所有權
70.6% of Concert Pharmaceuticals shares are owned by institutional investors. 17.8% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 11.3% of Concert Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Concert製藥公司70.6%的股份由機構投資者持有。Aerovate治療公司17.8%的股份由公司內部人士持有。相比之下,Concert PharmPharmticals 11.3%的股份由公司內部人士持有。強大的機構持股表明,對衝基金、捐贈基金和大型基金管理公司相信,一隻股票有望實現長期增長。
Summary
摘要
Aerovate Therapeutics beats Concert Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Aerovate治療公司在兩隻股票比較的11個因素中有6個擊敗了Concert PharmPharmticals。
About Aerovate Therapeutics
關於Aerovate Treatetics
(Get Rating)
(獲取評級)
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate治療公司是一家臨牀階段的生物製藥公司,專注於開發能夠改善美國罕見心肺疾病患者生命的藥物。該公司專注於推進AV-101,這是一種治療肺動脈高壓的伊馬替尼乾粉吸入劑,目前處於2b期/3期試驗。Aerovate治療公司成立於2018年,總部設在馬薩諸塞州沃爾瑟姆。
About Concert Pharmaceuticals
關於Concert製藥公司
(Get Rating)
(獲取評級)
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
康納製藥公司是一家臨牀階段的生物製藥公司,開發用於治療自身免疫性疾病的新型小分子藥物。該公司的主要候選產品是CTP-543,它正處於治療斑禿的第三階段臨牀試驗,斑禿是一種嚴重的自身免疫性皮膚病。它與Avanir製藥公司、Jazz製藥公司、Cipla技術公司和Processa製藥公司有戰略合作。該公司成立於2006年,總部設在馬薩諸塞州列剋星敦。
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Aerovate治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Aerovate治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧